SCHEMBL4228437

SCHEMBL4228437

CCOC(=O)CCCn1ccnc1CN(Cc1ccc(CN2CCC3(CCN(CC(C)C)CC3)C2)cc1)Cc1ncc[nH]1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 4/20 0.55
MEN1 O00255 3/20 0.37
MAPK1 P28482 3/20 0.37
KMT2A Q03164 3/20 0.37
MAPT P10636 1/20 0.35
TNF P01375 1/20 0.33
LMNA P02545 1/20 0.33
CYP3A4 P08684 5/20 0.32
CYP2D6 P10635 3/20 0.32
CYP1A2 P05177 1/20 0.32
KDM1A O60341 1/20 0.32
MAOB P27338 1/20 0.32
RCOR1 Q9UKL0 1/20 0.32
USP2 O75604 1/20 0.31
TSHR P16473 1/20 0.31
ALDH1A1 P00352 2/20 0.31
CTSD P07339 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4068813 0.91 CXCR4 (0.49) CXCR4MEN1MAPK1KMT2AMAPT
SCHEMBL4233522 0.91 CXCR4 (0.46) CXCR4MEN1MAPK1KMT2AMAPT
SCHEMBL4233758 0.91 CXCR4 (0.59) CXCR4MEN1MAPK1KMT2ACYP3A4
SCHEMBL4224701 0.91 CXCR4 (0.45) CXCR4MEN1MAPK1KMT2AMAPT
SCHEMBL4068773 0.90 CXCR4 (0.49) CXCR4MEN1MAPK1KMT2AMAPT
SCHEMBL4075342 0.90 CXCR4 (0.49) CXCR4MEN1MAPK1KMT2AMAPT
SCHEMBL4074202 0.89 CXCR4 (0.50) CXCR4MEN1MAPK1KMT2AMAPT
SCHEMBL4077532 0.88 CXCR4 (0.48) CXCR4MEN1MAPK1KMT2AMAPT
SCHEMBL4230314 0.88 CXCR4 (0.43) CXCR4MEN1MAPK1KMT2AMAPT
SCHEMBL4071713 0.87 CXCR4 (0.51) CXCR4MEN1MAPK1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8618122-B2 Compound having acidic group which may be protected, and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-12-31 US claimed
EP-2042503-B1 COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-01-30 EP claimed
EP-2042503-A1 COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-04-01 EP claimed
US-8618122-B2 Compound having acidic group which may be protected, and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-12-31 US disclosed
EP-2042503-B1 COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-01-30 EP disclosed
US-20090192182-A1 COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF ONO PHARMACEUTICAL CO.,LTD. (JP) 2009-07-30 US disclosed
EP-2042503-A1 COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192182-A1 COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF CXCR4, CXCR3, CXCL12 CXCR4 1/4885MEN1 2059/4885MAPK1 904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.